Patents by Inventor Huining Kang

Huining Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Gene Expression Signatures for Detection of Underlying Philadelphia Chromosome-like (Ph-like) Events and Therapeutic Targeting in Leukemia
    Publication number: 20200318197
    Abstract: The invention provides arrays, systems, devices, methods, computer-readable media and kits that enable expression-based classification of B-precursor acute lymphoblastic leukemia (ALL) as being either responsive or non-responsive to tyrosine kinase inhibitor mono or co-therapy.
    Type: Application
    Filed: December 18, 2019
    Publication date: October 8, 2020
    Inventors: Cheryl L. Willman, Stephen P. Hunger, Charles Mullighan, I-Ming Chen, Kathryn G. Roberts, Huining Kang, Richard C. Harvey
  • GENE EXPRESSION SIGNATURES FOR DETECTION OF UNDERLYING PHILADELPHIA CHROMOSOME-LIKE (PH-LIKE) EVENTS AND THERAPEUTIC TARGETING IN LEUKEMIA
    Publication number: 20170298449
    Abstract: The invention provides arrays, systems, devices, methods, computer-readable media and kits that enable expression-based classification of B-precursor acute lymphoblastic leukemia (ALL) as being either responsive or non-responsive to tyrosine kinase inhibitor mono or co-therapy.
    Type: Application
    Filed: June 30, 2017
    Publication date: October 19, 2017
    Inventors: Cheryl L. Willman, Stephen P. Hunger, Charles Mullighan, I-Ming Chen, Kathryn G. Roberts, Huining Kang, Richard C. Harvey
  • GENE EXPRESSION SIGNATURES FOR DETECTION OF UNDERLYING PHILADELPHIA CHROMOSOME-LIKE (PH-LIKE) EVENTS AND THERAPEUTIC TARGETING IN LEUKEMIA
    Publication number: 20140322166
    Abstract: The invention provides arrays, systems, devices, methods, computer-readable media and kits that enable expression-based classification of B-precursor acute lymphoblastic leukemia (ALL) as being either responsive or non-responsive to tyrosine kinase inhibitor mono or co-therapy.
    Type: Application
    Filed: December 12, 2012
    Publication date: October 30, 2014
    Applicant: STC. UNM
    Inventors: Cheryl L. Willman, Stephen P. Hunger, Charles Mullighan, I-Ming Chen, Kathryn G. Roberts, Huining Kang, Richard C. Harvey
  • GENE EXPRESSION CLASSIFIERS FOR RELAPSE FREE SURVIVAL AND MINIMAL RESIDUAL DISEASE IMPROVE RISK CLASSIFICATION AND OUTCOME PREDICTION IN PEDIATRIC B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
    Publication number: 20110230372
    Abstract: The present invention relates to the identification of genetic markers patients with leukemia, especially including acute lymphoblastic leukemia (ALL) at high risk for relapse, especially high risk B-precursor acute lymphoblastic leukemia (B-ALL) and associated methods and their relationship to therapeutic outcome. The present invention also relates to diagnostic, prognostic and related methods using these genetic markers, as well as kits which provide microchips and/or immunoreagents for performing analysis on leukemia patients.
    Type: Application
    Filed: November 16, 2009
    Publication date: September 22, 2011
    Inventors: Cheryl L. Willman, Richard Harvey, Huining Kang, Edward Bedrick, Xuefei Wang, Susan R. Atlas, I-Ming Chen
  • Outcome prediction and risk classification in childhood leukemia
    Publication number: 20090203588
    Abstract: Genes and gene expression profiles useful for predicting outcome, risk classification, cytogenetics and/or etiology in pediatric acute lymphoblastic leukemia (ALL). OPAL1 is a novel gene associated with outcome and, along with other newly identified genes, represent a novel therapeutic targets.
    Type: Application
    Filed: June 8, 2007
    Publication date: August 13, 2009
    Inventors: Cheryl L. Willman, Paul Helman, Robert Veroff, Monica Mosquera-Caro, George S. Davidson, Shawn B. Martin, Susan R. Atlas, Erik Andries, Huining Kang, Jonathan J. Shuster, Xuefei Wang, Richard C. Harvey, David M. Haaland, Jeffrey W. Potter
  • Molecular technologies for improved risk classification and therapy for acute lymphoblastic leukemia in children and adults
    Publication number: 20060141504
    Abstract: The present invention relates to methods for predicting the outcome of therapeutic intervention in cases of leukemia, especially acute lymphoblastic leukemia in children and adults. The present invention evaluates a gene expression profile and identifies prognostic genes of cancers, in particular leukemia, more particularly B-precursor acute lymphoblastic leukemia (ALL). The present invention provides a method of determining prognosis of leukemia, in particular, acute lymphoblastic leukemia, more particularly B-precursor ALL and predicting therapeutic outcome of a patient. The method comprises the steps of first establishing the threshold value of at least three prognostic genes of leukemia, preferably at least eight prognostic genes, or preferably, as many as 26 prognostic genes. Then, the amount of the prognostic gene(s) from a leukemia patient is determined.
    Type: Application
    Filed: November 23, 2005
    Publication date: June 29, 2006
    Inventors: Cheryl Willman, Edward Bedrick, Huining Kang, Paul Helman, Robert Veroff
  • Outcome prediction and risk classification in childhood leukemia
    Publication number: 20060063156
    Abstract: Genes and gene expression profiles useful for predicting outcome, risk classification, cytogenetics and/or etiology in pediatric acute lymphoblastic leukemia (ALL). OPAL1 is a novel gene associated with outcome and, along with other newly identified genes, represent a novel therapeutic targets.
    Type: Application
    Filed: December 5, 2003
    Publication date: March 23, 2006
    Inventors: Cheryl Willman, Paul Helman, Robert Veroff, Monica Mosquera-Caro, George Davidson, Shawn Martin, Susan Atlas, Erik Andries, Huining Kang, Jonathan Shuster, Xuefei Wang, Richard Harvey, David Haaland, Jeffrey Potter